Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. Supply-side sources consist of CEOs, Chief Scientific Officers (CSOs), VPs of Genomics, regulatory affairs heads, bioinformatics directors, and commercial leaders from nutrigenomics testing companies, personalized nutrition platforms, genomic assay manufacturers, and functional food developers. Registered dietitian nutritionists (RDNs), clinical genomics specialists, metabolic disorder clinicians, medical directors of corporate wellness programs, procurement officers from hospitals and diagnostic laboratories, and research scientists from academic nutrigenomics centers comprised demand-side sources. Primary research has confirmed the timelines of genetic testing pipelines, validated market segmentation across obesity management, cardiovascular health, and metabolic disorder applications, and gathered insights on the clinical adoption of personalized nutrition protocols, DTC pricing strategies, bioinformatics platform integration, and regulatory compliance for gene-based health claims.
Primary Respondent Breakdown:
By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)
By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)
Global market valuation was derived through revenue mapping and genetic testing volume analysis. The methodology included:
Identification of 50+ key manufacturers and service providers across North America, Europe, Asia-Pacific, and Latin America specializing in genetic testing kits, reagents, bioinformatics platforms, and personalized nutrition services
Product mapping across gene panels for macronutrient metabolism, micronutrient absorption, food intolerance, obesity risk, cardiovascular markers, and sports performance categories
Analysis of reported and modeled annual revenues specific to nutrigenomics portfolios, including DTC testing subscriptions and clinical diagnostic services
Coverage of manufacturers and service providers representing 75-80% of global market share in 2024
Extrapolation using bottom-up (genetic test volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations across testing kits, nutritional supplements, and digital health platforms